STOCK TITAN

CareDx to Report First Quarter 2023 Financial Results

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

BRISBANE, Calif.--(BUSINESS WIRE)-- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2023 after market close on Wednesday, May 10, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Individuals interested in listening to the conference call may do so by dialing 1-800-732-8470 for domestic callers or 1-212-231-2912 for international callers. Please reference Conference ID: 22026935. To listen to a live webcast, please visit the investor relations section of CareDx’s website at: investors.caredxinc.com.

About CareDx – The Transplant Company

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

CareDx, Inc.

Investor Relations

Greg Chodaczek

investor@caredx.com

Source: CareDx, Inc.

CareDx, Inc.

NASDAQ:CDNA

CDNA Rankings

CDNA Latest News

CDNA Stock Data

1.22B
51.79M
3.44%
96.1%
6.43%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
BRISBANE